Close Menu

Applied Biocode

The firm will use the funds to commercialize its newly cleared molecular diagnostics platform and gastrointestinal pathogen panel test.

The BioCode GPP tests for 17 of the most common bacteria, viruses, and parasites that cause infectious diarrhea, and runs on the BioCode MDx-3000 system.

The company submitted the platform and gastrointestinal panel to the US Food and Drug Administration for clearance earlier this year.

The Gastrointestinal Pathogen Panel is the first of a number of planned infectious disease syndromic panels on the firm's PCR-based system. 

Applied Biocode intends to have panel for identifying 18 gastrointestinal pathogens on the clinical market by the end of the year.

The companies will use their respective technologies to develop multiplex molecular diagnostic panels for laboratory testing.

The deal covers use within the life sciences, food and beverage research, and environmental testing markets.

The deal provides PerkinElmer access to Applied BioCode's Barcoded Magnetic Bead technology, including the BioCode MDx 3000 instrument.

Genetic Analysis CEO Kari Stenersen said the deal is a "commercial breakthrough" for the Oslo-based company.

NEW YORK (GenomeWeb) — Applied BioCode is developing a new test for gastrointestinal pathogens that it hopes to sell to high-volume hospital laboratories and that will compete directly with Luminex's US Food and Drug Administration-cleared Gastrointestinal Pathogen Panel.

Pages

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.